2022
- OEP Group Headquarter is relocated at Beitou Shilin Technology Park in Taipei
- OP NanoPhama awarded TFDA PIC/S GMP certification
2019
- Established US subsidiary, focusing on the next frontier of pharmaceutical R&D and business development
- Orient PHARMA Co., Ltd obtained US FDA approval of Vancomycin Hydrochloride Capsules USP and Glyburide Tablets USP
2018
- Orient PHARMA Co., Ltd's self-developed drug - Methydur®, for the treatment of ADHD had been approved by TFDA and became the first country to launch the product
- Construction of the production facilities for subsidiary OP NanoPharma Co., Ltd was completed, marking the beginning of use of Nano-particle Micellar Delivery Technology to produce anti-cancer injectable solutions and powders
2017
- OEP obtained letter of approval from Taiwan Food and Drug Administration for human organ bank
- A subsidiary was established in Indonesia, expanding the Southeast Asian market
2016
- The first anti-hyperlipidemia drug developed by OEP was officially launched in Taiwan
- OEP signed a cooperative agreement with American company TissueTech, acquiring exclusive rights for the next series of ophthalmologic tissue products in Asia Pacific and stepping into the field of regenerative medicine
- OEP entered a cooperative agreement with Second Sight, acquiring exclusive distribution rights for the Argus II Retinal Prosthesis System in Taiwan and entering the field of ophthalmology
2014
- Orient PHARMA Co., Ltd had its first ANDA approved by US FDA, officially entered US market
- Signed agreement with Japan’s NanoCarrier Co., Ltd. to develop new cancer drug and construct a new plant
2013
- Orient PHARMA Co., Ltd awarded US Food and Drug Administration Manufacturing Plant Inspection certification
2012
- OEP established a professional dermo-cosmetics sales team in the Philippines, setting up its dermo-cosmetics business in overseas market for the first time
- Orient PHARMA Co., Ltd awarded Japan’s official foreign pharmaceutical manufacturer certification
- Orient PHARMA Co., Ltd officially listed for OTC trading (Stock Code: 4166)
2011
- Orient PHARMA Co., Ltd awarded Taiwan’s Food and Drug Administration PIC/S GMP certification
2010
- Established office in Vietnam, enhancing Southeast Asian channels
2008
- “Karihome” series marketed in China, which Established subsidiary company, Orient PHARMA Co., Ltdwas the first product of OEP entering China market
- Established subsidiary company, Orient PHARMA Co., Ltd
2004
- “Karihome” series marketed in Hong Kong
2003
- Imported Swedish injectable hyaluronic acid products, becoming the first company in Taiwan to obtain government permit for brands with hyaluronic acid
- Officially listed for OTC trading (Stock Code: 4120)
2002
- “Karihome” series marketed in Singapore and Malaysia, setting up its business in overseas market for the first time
- Established new offices in Philippines, further expanding the Company’s Southeast Asian territory
- Established the Dermo-cosmetics Division and entered the skincare market
1999
- OEP began deploying its overseas channels in Singapore, Malaysia, and Hong Kong, entering the Southeast Asian markets with prescription medicines
- Invested in the GMP pharmaceutical plant and medical R&D
1989
- Imported infant goat formula from New Zealand, and created the first private brand “Karihome” for domestic sales in Taiwan
1982
- Founded Orient EuroPharma Co., Ltd and marketed prescription medicines
Honor
2023
- Ranked 603rd among the top thousand large enterprises named by Common Wealth Magazine
2022
- Ranked 592nd among the top thousand large enterprises named by Common Wealth Magazine
- Ranked 89th among the top 100 Bio-Technology enterprises named by Business Today Magazine
2021
- Ranked 487th among the top thousand large enterprises named by Common Wealth Magazine
2020
- Methydur won the TFDA/MOEA Drug Technology R&D Silver Award
- Ranked 442nd among the top thousand large enterprises named by CommonWealth Magazine
2019
- Orient PHARMA Co., Ltd (Methydur Sustained Release Capsules) awarded the Innovation of the Year of 2019 Taiwan Bio-Industry Organization Awards
2018
- The subsidiary in Singapore was ranked 88th in the 2015 and 2016 Top 100 Taiwanese Business in ASEAN for revenue and profit growth
2017
- Ranked 484th among the top thousand large enterprises named by CommonWealth Magazine
2016
- Ranked 508th among the top thousand large enterprises named by CommonWealth Magazine
2015
- Ranked 85th among the top hundred companies which the new generation of Taiwan most long for
- Orient EuroPharma Co., Ltd was named again as one of Benchmark Pharmaceutical Company (Bio Taiwan Highlight) By IBMI (Institute for Biotechnology and Medicine Industry)
- Ranked 526th among the top thousand large enterprises named by CommonWealth Magazine
2014
- Orient EuroPharma Co., Ltd achieved class A+ for the 11th annual Information Enclosure Evaluation
- Ranked 538th among the top thousand large enterprises named by CommonWealth Magazine
2013
- Orient EuroPharma Co., Ltd named as one of the top three benchmark biotechnology by the Institute for Biotechnology and Medicine Industry
- Orient EuroPharma Co., Ltd achieved class A+ for the 10th annual Information Enclosure Evaluation
- Ranked 549th among the top thousand large enterprises named by CommonWealth Magazine
2012
- Ranked 600th among the top thousand large enterprises named by CommonWealth Magazine
2011
- Honored with the 1st Gre Tai Securities Market Golden Laurel Award for excellent and sustainable enterprise
- Orient EuroPharma Co., Ltd achieved class A+ for the 8th annual Information Enclosure Evaluation
2010
- Orient EuroPharma Co., Ltd achieved class A+ for the 7th annual Information Enclosure Evaluation
2007
- Orient EuroPharma Co., Ltd achieved class A+ for the 4th annual Information Enclosure Evaluation